# Can Exercise Training Improve the Quality of Life and Physical Function in Multiple Myeloma Patients?: Discussing the Progression of the Training Stimulus

**Authors:** Polyxeni Spiliopoulou, Evangelos Eleutherakis-Papaiakovou, Magdalini Migkou, Nikolaos Kanellias, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Foteini Theodorakakou, Despina Fotiou, Pantelis Rousakis, Chrysanthi Panteli, Evangelos Terpos, Maria Gavriatopoulou, Ourania E. Tsitsilonis, Efstathios Kastritis, Meletios Athanasios Dimopoulos, Gerasimos Terzis

PMC · DOI: 10.3390/sports14020061 · Sports · 2026-02-04

## TL;DR

This study explores whether exercise training can improve quality of life and physical function in multiple myeloma patients, finding limited improvements despite some positive effects on strength.

## Contribution

The study investigates why previous exercise interventions failed in multiple myeloma patients, suggesting inconsistent training progression and the need for supervision.

## Key findings

- Exercise training significantly improved six-minute walking test distance but not quality of life or maximal aerobic power.
- Maximal isometric strength increased significantly in both exercise and control groups.
- The difference in outcomes between groups was not statistically significant, suggesting inconsistent training progression.

## Abstract

Background: Previous studies have reported no improvements in quality of life or physical function following exercise training in patients with multiple myeloma, without a clear explanation. The purpose of the present study was to examine the effects of an exercise-training intervention on these outcomes and to determine whether the observed results could be explained by the characteristics of the training program. Methods: Sixteen patients with multiple myeloma who had completed first-line induction therapy were assigned to two groups. One group (2 men, 6 women, 52.6 ± 10.3 years) commenced maintenance therapy only, while the other group (2 men, 6 women, 58.8 ± 7.1 years) initiated maintenance therapy combined with a supervised exercise training program conducted twice per week. Each exercise session included 30 min of cycling and seven resistance exercises targeting the major muscle groups. The intervention lasted 4.4 ± 1 months. QoL, the six-minute walking test, handgrip strength, maximal aerobic power, maximum isometric contraction across 14 positions, and bone density were assessed before and after the intervention. Results: The six-minute walking test distance significantly increased in the exercise group (9.36 ± 6.88%, p = 0.001), while no change was observed in the control group (3.34 ± 5.68%, p = 0.162); however, the difference between groups was not statistically significant (p = 0.076). QoL and maximal aerobic power remained unchanged in both groups, while maximal isometric strength increased significantly in both groups. Conclusions: The progression of the training stimulus appears to be inconsistent in this specific population, potentially limiting improvements in quality of life and physical function outcomes. Supervision appears to be necessary for exercise training in patients with multiple myeloma. Future research should investigate alternative exercise modalities in these patients.

## Linked entities

- **Diseases:** multiple myeloma (MONDO:0009693)

## Full-text entities

- **Genes:** CD38 (CD38 molecule) [NCBI Gene 952] {aka ADPRC 1, ADPRC1, cADPR1}
- **Diseases:** injuries (MESH:D014947), Pain (MESH:D010146), fractures (MESH:D050723), pancreatic cancer (MESH:D010190), coronary disease (MESH:D003327), Insomnia (MESH:D007319), Dyspnea (MESH:D004417), Multiple Myeloma (MESH:D009101), Renal failure (MESH:D051437), Cancer (MESH:D009369), head and neck cancer (MESH:D006258), nausea (MESH:D009325), Fatigue (MESH:D005221), Diarrhea (MESH:D003967), osteolytic lesions (MESH:D030981), vomiting (MESH:D014839), financial difficulties (MESH:D051346), Anemia (MESH:D000740), hyperCalcemia (MESH:D006934), Bone lesions (MESH:D001847), osteoporosis (MESH:D010024), Nausea and Vomiting (MESH:D020250), Appetite loss (MESH:D001068), Constipation (MESH:D003248), neuromuscular disorders (MESH:D009468)
- **Chemicals:** calcium (MESH:D002118)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12945274/full.md

## References

36 references — full list in the complete paper: https://tomesphere.com/paper/PMC12945274/full.md

---
Source: https://tomesphere.com/paper/PMC12945274